Vascular Remodeling and the Effects of Angiogenic Inhibition in Diabetic Retinopathy

NCT00411333 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

100

Enrollment

NIH

Sponsor class

Conditions

Diabetic Retinopathy

Interventions

DRUG: triamcinolone acetonide (Kenalog)

Sponsor

National Eye Institute (NEI)